Recent studies have reported that a larger treatment effect is observed in ER+, HER2− advanced breast cancer patients treated with ET when outcomes are analysed by PIK3CAmut positivity in ctDNA compared to the same analysis by tissue PIK3CAmut positivity [6, 10, 16]. This evidence concerns the gene ESR1 and breast cancer.